摘要:
The invention refers to a novel pharmaceutical composition having especially antimycotic activity and comprising the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline of formula (I) ##STR1## and one or more pharmaceutically acceptable carriers. The pharmaceutical composition of the invention can be used for the effective treatment of mycotic infections on the skin surface, mucous membranes or nails.The complex of formula (I) is prepared by reacting a solution of an alkali metal salt of 5-chloro-7-iodo-8-hydroxyquinoline with a solution containing an excess of an inorganic or organic zinc salt or a zinc complex having a lower stability constant than that of the complex of formula (I) and separating the product precipitated.
摘要:
The invention relates to a process for the preparation of dimethyl-1,4-dihydro-2,6-dimethyl-4-(2'-nitro-phenyl)-pyridine-3,5-dicarboxylate of the Formula I ##STR1## which comprises a) reacting a compound of the general Formula II ##STR2## (wherein n is 1 or 3; if n is 1, then R stands for a group of the Formula (a) ##STR3## and if n is 3, then R represents hydrogen) with methyl acetoacetate of the Formula IIICH.sub.3 --CO--CH.sub.2 --COOCH.sub.3 (III) and optionally with an amino compound of the general Formula IV ##STR4## (wherein Z is a group of the Formula (c), ##STR5## k is 1 and both symbols p are 0; or Z stands for a C.sub.1-5 straight or branched chain alkanoyloxy group or a carbonate, hydrocarbonate or hydroxy anion, k is 1 and both symbols p are 1; or k is 0, one of both symbols p is 0 and the other is 1) in an inert solvent; orb) reacting 2-nitro-benzaldehyde and methyl acetoacetate of the Formula III and aqueous ammonium hydroxide in the presence of an inert solvent in one step, at a temperature of 101.degree.-120.degree. C., under a pressure of 2.0-6.0 bar.
摘要:
The invention relates to weight gain-increasing compositions, particularly fodder supplement, premix, drinking water supplement, bolus and/or microcapsule containing 0.001 to 90% by weight of 1-(3,5-dihydroxyphenyl)-2-(tertiary butylamino)-ethanol or a physiologically acceptable acid addition salt thereof as active ingredient in admixture with inert solid and/or liquid carrier(s).
摘要:
The compounds of the general Formula I ##STR1## (wherein R.sup.1 and R.sup.2 may be the same or different and each stands for hydrogen, hydroxy, C.sub.1-6 alkoxy, C.sub.1-6 alkoxy-C.sub.1-6 alkoxy, C.sub.2-6 alkenyloxy or phenyl-(C.sub.1-3 alkoxy), or R.sup.1 and R.sup.2 together form C.sub.1-2 alkylenedioxy; with the proviso that at least one of symbols R.sup.1 and R.sup.2 is other than hydrogen and with the further proviso that R.sup.1 and R.sup.2 can not represent 3,4-dimethoxy substitution) andtheir pharmaceutically acceptable acid addition salts exhibit useful analgesic, antipyretic, anti-inflammatory, anti-anginal and antioxidant effect.
摘要:
The invention relates to pharmaceutical compositions having analgesic and/or anti-inflammatory effect comprising as active ingredient 2,4-diamino-5-(3,4-dimethoxy-benzyl)-pyrimidine or a pharmaceutically acceptable acid addition salt thereof.The pharmaceutical compositions of the present invention exhibit the desired analgesic and anti-inflammatory effect without causing undesired ulcerogenic side-effects.
摘要:
The invention refers to a novel pharmaceutical composition having especially antimycotic activity and comprising the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline of formula (I) ##STR1## and one or more pharmaceutically acceptable carriers. The pharmaceutical composition of the invention can be used for the effective treatment of mycotic infections on the skin surface, mucous membranes or nails.The complex of formula (I) is prepared by reacting a solution of an alkali metal salt of 5-chloro-7-iodo-8-hydroxyquinoline with a solution containing an excess of an inorganic or organic zinc salt or a zinc complex having a lower stability constant than that of the complex of formula (I) and separating the product precipitated.
摘要:
The invention is directed to processes for the preparation of dimethyl-1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)-pyridine-3,5-dicarboxylate by reacting 1-methoxy-1-(2'-nitrophenyl)-N-(2'-nitrophenyl)methylene methanamie or 1-(2'-nitrophenyl)-N,N'-bis-(2'-nitrophenyl) methylene methanediamine with methyl acetoacetate in the presence of an amine compound or by reacting the monomeric or trimeric from of 2-nitrobenzaldimine with methyl acetoacetate.